Terms: = Ovarian cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Prognosis
3 results:
1. Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients.
Soltész B; Lukács J; Szilágyi E; Márton É; Szilágyi Bónizs M; Penyige A; Póka R; Nagy B
J Biotechnol; 2019 Jun; 298():16-20. PubMed ID: 30959137
[TBL] [Abstract] [Full Text] [Related]
2. The expression profile and prognostic value of APE/Ref-1 and npm1 in high-grade serous ovarian adenocarcinoma.
Fan X; Wen L; Li Y; Lou L; Liu W; Zhang J
APMIS; 2017 Oct; 125(10):857-862. PubMed ID: 28766835
[TBL] [Abstract] [Full Text] [Related]
3. Inhibitors of the apurinic/apyrimidinic endonuclease 1 (APE1)/nucleophosmin (npm1) interaction that display anti-tumor properties.
Poletto M; Malfatti MC; Dorjsuren D; Scognamiglio PL; Marasco D; Vascotto C; Jadhav A; Maloney DJ; Wilson DM; Simeonov A; Tell G
Mol Carcinog; 2016 May; 55(5):688-704. PubMed ID: 25865359
[TBL] [Abstract] [Full Text] [Related]
